Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers in clozapine-responding schizophrenia
2024-515338-34-01Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clozapine in schizophrenia, schizoaffective disorder and Schizophrenia Spectrum Disorders (SSD), sponsored by Capital Region of Denmark. Planned start Oct 2024; status: authorised.
02
Drugs
clozapine
03
Conditions
schizophreniaschizoaffective disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2024-515338-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515338-34-01.